Mayo Clinic Researchers Identify Promising Therapy for Lichen Planus
A groundbreaking study by Mayo Clinic researchers has pinpointed a targeted therapy that could offer relief to individuals with lichen planus, a common chronic inflammatory condition affecting the skin, hair, nails, mouth, and genitals.
Published in the Journal of Clinical Investigation, the research details the first-in-human, phase 2 clinical trial targeting specific molecular and cellular changes in the skin associated with lichen planus.
Understanding Lichen Planus
Lichen planus is a condition that afflicts approximately 1 to 2% of the general population, significantly impacting daily life with symptoms such as intense itching or pain. On the skin, it typically manifests as purple, itchy, flat bumps. In oral and genital areas, it forms lacy white patches and can lead to painful sores.
Treating lichen planus is challenging, with few disease-specific medications available. Current treatments focus primarily on symptom management, often accompanied by side effects like skin thinning and an increased risk of infection.
The Role of Immune System in Lichen Planus
The Mayo Clinic team discovered unique immune system changes in individuals with lichen planus, particularly noting an overactive immune response involving certain types of T cells. These T cells mistakenly attack normal cells, causing inflammation.
Interferon-gamma, a critical cytokine, plays a key role in this abnormal immune response. Cytokines are vital proteins that control immune and blood cell functions. In lichen planus, interferon-gamma is overabundant, exacerbating the inflammation.
Introduction of Baricitinib
The researchers used baricitinib, a medication designed to block specific inflammatory pathways, to address these issues. Baricitinib, an oral Janus kinase (JAK) 1/2 inhibitor, hinders the signaling pathway of interferon-gamma by inhibiting JAK enzymes. This action reduces inflammation and suppresses the overactive immune response responsible for symptoms.
Successful Trial Results
The study included patients with treatment-refractory disease who showed early and sustained improvements after baricitinib treatment. Within 16 weeks, there was an 83% improvement in symptom responsiveness, representing a substantial enhancement over baseline conditions.
Baricitinib also rapidly decreased interferon activity, a key signaling molecule in lichen planus, reducing specific pathogenic T-cells and addressing the root cause of the condition.
This research is an important step in understanding and treating autoimmune and inflammatory diseases. These findings provide a potential new, effective, disease-specific treatment option for lichen planus and therapeutic targets for other inflammatory diseases.
Aaron R. Mangold, M.D., senior author, dermatologist, and researcher with the Mayo Clinic Comprehensive Cancer Center at Mayo Clinic, Phoenix
Implications for Future Treatments
Dr. Mangold, a Mayo Clinic consultant in dermatology, emphasized the study’s significance in gaining insights into lichen planus’ pathophysiology and the promise of baricitinib as an innovative treatment. He previously conducted a phase 2 Mayo Clinic-led clinical trial targeting similar immune cells.
Dr. Mangold’s team has been instrumental in studying rare inflammatory conditions and developing new therapies. This research not only offers hope for individuals with lichen planus but also opens avenues for treating other inflammatory diseases.
Conclusion
The identification of baricitinib as a potential treatment for lichen planus marks a significant advancement in managing this chronic condition. By targeting the overactive immune response and reducing inflammation, the therapy shows promising results for both symptom relief and therapeutic outcomes.
As the research community continues to explore the potential of this drug and similar treatments, individuals suffering from lichen planus may find safer and more effective options for improving their quality of life.
We invite you to share your thoughts on this groundbreaking discovery in the comments below. If you found this article informative, please don’t hesitate to subscribe to our newsletter or share it on your social media platforms to spread the word. Together, we can stay informed about the latest advancements in medical research.
